In this episode of Product in Healthtech, we reconnect with Scott Martin, founder and CEO of Rescription, to discover how his company has evolved since our previous conversation.

Topics covered:

• Rescription's "radical clarity" approach to transforming prescription drug costs
• How Rescription leverages the 340B federal program as intended to benefit both health systems and patients
• Results from partnerships with Bergen New Bridge and Baton Rouge General, showing 27-35% savings
• Why patients under Rescription's model receive zero-dollar copays for prescriptions
• The patent-pending adjudication technology developed with Vynyl that enables upfront processing at scale
• Rescription's ambitious expansion plans across 14 states and 15 additional health systems

Key moments:

• [01:16] Scott explains how Rescription's model differs from traditional PBMs
• [03:09] Clarifying misconceptions about the 340B program
• [05:14] Updates on partnerships with Bergen New Bridge and Baton Rouge General
• [07:25] How Rescription addresses pharmaceutical manufacturer pushback
• [09:24] Details on Rescription's patent-pending adjudication technology
• [11:15] Future expansion plans and new service offerings

Resources mentioned:

• Wall Street Journal article featuring Rescription: https://www.wsj.com/health/healthcare/prescription-drug-prices-340b-pharmacy-benefit-plans-6834cc08

Follow Product in Healthtech:

• Website: productinhealthtech.com
• LinkedIn: Product in Healthtech
• Email: [email protected]

Product in Healthtech is community for healthtech product leaders, by product leaders. For more information, and to sign up for our free webinars, visit www.productinhealthtech.com.